Get updates on COVID-19 research at COVID-19 Resource
Crop Biotech Update

Pfizer and Protalix BioTherapeutics Derive GE Carrot Cells for Gaucher Disease Treatment

May 11, 2012

A new announcement from Pfizer, Inc. and ProtalixBioTherapeutics said that the U.S. Food and Drug Administration (FDA) has approved the ELELYSO™ for injection. This new drug is for the enzyme replacement therapy (ERT) of adults with type 1 Gaucher disease.

ELELYSO™ is the first plant cell-based ERT that FDA has approved. This new drug is derived from ProCellEx® using genetically engineered carrot cells. ProCellEx® is Protalix's proprietary manufacturing system.

Read more about ELELYSO™ and the plant cell manufacturing system at http://www.pfizer.com/news/press_releases/pfizer_press_release.jsp?guid=20120501007295en&source=RSS_2011&page=1.